GeneDx is trading 4.46% down at $82.10 on September 29, 2026; no specific announcement or credible report has tied the intraday decline to a new catalyst.
- Recent investor concerns include proposed Medicare reimbursement cuts, the company’s reduced 2026 revenue outlook, and analyst price-target reductions; these are prior context, not confirmed causes of today’s move.
- Broad indexes are mixed, and the supplied market context does not clearly explain the drop.